Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in Trial 31-08-250~* De novo subjects not participating in Trial 31-08-250~* Subjects who are able to provide written informed consent.~* Male and female subjects 18 years of age or older at time of informed consent~* Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication for their bipolar I disorder and would benefit from extended treatment with a long-acting injectable formulation~* Subjects who have a recurrence of mood episode or exacerbations of mood symptoms when they are not receiving treatment for their bipolar I disorder or are noncompliant with treatment for their bipolar I disorder~* Have an outpatient status~Exclusion Criteria:~* Experienced 9 or more mood episodes within the past year~* A current manic episode with a duration of \> 2 years~* Currently meet DSM-IV-TR criteria for substance abuse or substance dependence; this includes the abuse of alcohol and benzodiazepines, but excludes the use of caffeine and/or nicotine~* Hypothyroidism or hyperthyroidism, unless condition has been stabilized~* Diagnosed with epilepsy or a history of seizures~* Known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones~* Sexually active women of childbearing potential and sexually active men who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during this trial and for 180 days following the last dose of trial medication~* Females breastfeeding or pregnant (positive blood pregnancy test prior to receiving trial drug)~* Risk of committing suicide~* Abnormal laboratory test results, vital signs and ECG results~* Participated in any clinical trial other than Trial 250 with an investigational agent within the 30 days prior to screening~* Had electroconvulsive therapy (ECT) treatment during the current episode or within 3 months~* Subjects who have not met criteria for stabilization for 4 consecutive weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Aripiprazole, Intramuscular (IM) Depot

Based on this trial design, predict the completion outcome and termination type (if applicable).